Comparison of Comorbidities and Adverse Events in Dermatology and Rheumatology Patients Prescribed Tofacitinib: A Retrospective Analysis.

To the Editor: Tofacitinib was the first Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitor approved to treat certain rheumatologic conditions (eg rheumatoid arthritis).1 However, the US Food and Drug Administration did not extend similar approval to dermatologic conditions due to safety concerns and a lack of large clinical trials in dermatologic patients.2 Nevertheless, tofacitinib is used off-label for dermatologic diseases recalcitrant to Food and Drug Administration approved therapies.